Abstract
Summary: α2-Macroglobulin (α2M) is a major plasma protease inhibitor that has been studied because of its suggested role in the pathology of cystic fibrosis (CF). A panel of monoclonal antibodies specific for human α2M were produced and screened for their ability to bind to a number of human α2M samples. We have used these antibodies to characterize individual antigenic sites in this protein. α2M was purified from plasma by polyethylene glycol precipitation followed by zinc chelate chromatography. A total of 23 α2M samples in the native configuration, as well as the nucleophile-treated configuration, were screened by the panel of 18 monoclonal antibodies in an enzyme-linked immunosorbent assay procedure. Five of the samples tested were from individuals with cystic fibrosis. α2M from family members of two of these patients was subsequently tested for reactivity with the monoclonal antibodies. One antibody, SAM94, exhibited a significant difference in binding to α2M obtained from CF patients as compared with control individuals. This difference was particularly apparent in the binding of SAM94 to the nucleophile-treated CF α2M; SAM94 showed significantly reduced binding to four of five unrelated CF individuals (p < 0.005) and three of four cystic fibrosis obligate heterozygotes (p < 0.005).
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eager, K., Kennett, R. A Monoclonal Antibody Recognizes Structural Variation in Cystic Fibrosis α2-Macroglobulin. Pediatr Res 18, 999–1004 (1984). https://doi.org/10.1203/00006450-198410000-00018
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-198410000-00018